絞り込み

16403

広告

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity.

著者 Yang F , Lei Q , Li L , He JC , Zeng J , Luo C , Yeung SJ , Yang R
PLoS One.2017 ; 12(11):e0188025.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Full Text Sources

Continuous infusion of doxorubicin has been a strategy to reduce cardiotoxicity. Epirubicin is another anthracycline in common clinical use. However, evidence is lacking regarding whether this strategy can reduce cardiotoxicity of epirubicin without compromising antineoplastic efficacy.
PMID: 29131861 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード